Catalyst
Slingshot members are tracking this event:
Aquinox Pharmaceuticals Initiates Patient Dosing in LEADERSHIP 301 Phase 3 Clinical Trial of AQX-1125 in Interstitial Cystitis/Bladder Pain Syndrome
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
AQXP | Community voting in process |
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 06, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Leadership 301, Aqx-1125, Interstitial Cystitis, Bladder Pain Syndrome